These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 29254220)

  • 1. Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients.
    Arrieta O; Montes-Servín E; Hernandez-Martinez JM; Cardona AF; Casas-Ruiz E; Crispín JC; Motola D; Flores-Estrada D; Barrera L
    Oncotarget; 2017 Nov; 8(60):101994-102005. PubMed ID: 29254220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
    Meniawy TM; Lake RA; McDonnell AM; Millward MJ; Nowak AK
    Lung Cancer; 2016 Mar; 93():9-16. PubMed ID: 26898608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
    Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
    Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study.
    Wang Y; Zhu J; Zhou N; Wang Y; Zhang X
    J Thorac Dis; 2023 Oct; 15(10):5669-5679. PubMed ID: 37969284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
    Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
    World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Increased expressions of programmed death 1 (PD-1) and its ligands in peripheral CD3(+) T cells and CD19(+) B cells in patients with hepatocellular carcinoma].
    Liu W; Chai L; Liang J; Lu Z; Yang S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Sep; 32(9):1243-7. PubMed ID: 27609582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
    Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
    J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups.
    Miao C; Chen Y; Zhang H; Zhao W; Wang C; Ma Z; Zhu S; Hu X
    Transl Lung Cancer Res; 2024 Jun; 13(6):1264-1276. PubMed ID: 38973958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of PD-1/PD-L1 in peripheral blood mononuclear cells in lung cancer patients and its biological significance].
    Xu P; Chen H; Chen YJ; Chen YB; Gu GH; Wu MY; Wu MJ; Wang XF; Zhang XG
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):910-3. PubMed ID: 24506960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer.
    Ju X; Shen R; Huang P; Zhai J; Qian X; Wang Q; Chen M
    Oncotarget; 2017 Nov; 8(59):99372-99381. PubMed ID: 29245908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma.
    Shimauchi T; Kabashima K; Nakashima D; Sugita K; Yamada Y; Hino R; Tokura Y
    Int J Cancer; 2007 Dec; 121(12):2585-90. PubMed ID: 17721918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death-1
    Singh A; Mohan A; Dey AB; Mitra DK
    Clin Exp Immunol; 2017 Feb; 187(2):269-283. PubMed ID: 27665733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Biologic Treatment on PD-1/PD-L1 Pathway Disturbances in Psoriasis.
    Adamczyk M; Bartosińska J; Raczkiewicz D; Michalak-Stoma A; Krasowska D
    J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of PD-L1 and PD-L2 in dermal fibroblasts from alopecia areata mice.
    Li Y; Kilani RT; Pakyari M; Leung G; Nabai L; Ghahary A
    J Cell Physiol; 2018 Mar; 233(3):2590-2601. PubMed ID: 28777458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.
    Obeid JM; Erdag G; Smolkin ME; Deacon DH; Patterson JW; Chen L; Bullock TN; Slingluff CL
    Oncoimmunology; 2016; 5(11):e1235107. PubMed ID: 27999753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma.
    Kogashiwa Y; Yasuda M; Sakurai H; Nakahira M; Sano Y; Gonda K; Ikeda T; Inoue H; Kuba K; Oba S; Ishikawa J; Enoki Y; Matsumura S; Minami K; Ebihara Y; Sugasawa M
    Anticancer Res; 2017 Mar; 37(3):1417-1424. PubMed ID: 28314313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8
    Sheng J; Wang H; Liu X; Deng Y; Yu Y; Xu P; Shou J; Pan H; Li H; Zhou X; Han W; Sun T; Pan H; Fang Y
    Front Mol Biosci; 2021; 8():679130. PubMed ID: 34307450
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.